Where Peptides ARE Actually Made

How peptides are actually made

Solid Phase Peptide Synthesis (SPPS) is the core production process. The chemistry: each amino acid in the target peptide is attached one at a time to a resin support, then protected, washed, and coupled to the next amino acid. The cycle repeats for every single amino acid in the sequence. Once complete, the peptide is cleaved from the resin and purified through High-Performance Liquid Chromatography (HPLC).

This is not garage chemistry. SPPS requires:

• Equipment that costs hundreds of thousands of dollars (automated synthesizers, HPLC purification systems, lyophilization equipment)
• Sterile laboratory conditions
• Trained synthetic chemists to operate the synthesis and quality-control workflows
• Raw materials including protected amino acids, resins, coupling reagents, and solvents

The barrier to entry is genuinely high. You cannot make peptides at home the way some bodybuilders have historically brewed testosterone from raw powder. That distinction matters: it means the realistic universe of “where this peptide came from” is much smaller than the universe of “vendors selling peptides.” Production happens at a handful of facilities globally; everyone else is sourcing from those facilities and putting their own labels on the output.

The actual US peptide manufacturing landscape

Per industry-insider reporting (Holyfield 2026, verified independently against pharmaceutical industry press coverage), there are approximately five facilities in the United States that manufacture peptides at production scale. Verified specifics:

• CordenPharma Colorado (Boulder) — the largest US peptide CDMO. ~300 employees currently, expanding to 700+ via a $500 million expansion plan. Currently operating with ~10,000 L SPPS reactor capacity, with a 25,000 L expansion underway that will bring total reactor volume to 42,000+ L by 2028. Produces 2+ metric tons of peptides annually. Acquired from Roche in 2011. Their work is contracted to FDA-approved drugs and clinical-trial programs worth millions; they serve as a peptide-API supplier to major pharmaceutical companies including GLP-1 RA programs (the Corden Boulder expansion is specifically targeted at GLP-1 demand).
• AmbioPharm — Contract Development and Manufacturing Organization (CDMO) with facilities in both South Carolina AND Shanghai. The dual-facility setup is important because a vendor sourcing from AmbioPharm cannot necessarily claim “made in the US” — the same parent company can produce a peptide at either facility, and the customer-facing vendor often doesn’t disclose (or doesn’t know) which facility produced their specific batch.
• CPC Scientific — primarily based in Hangzhou, China. Their California facility is not expected to be operational until 2026.
• SK Pharmteco — California-based pharmaceutical CDMO. Their peptide capacity is also coming online in 2026.
• Bachem and Cambrex — established CDMOs handling pharmaceutical-grade API production across a broader scope than peptides alone.

The critical structural fact: these facilities are not selling small-batch research-chem orders. Their production is scheduled months in advance through multi-million-dollar pharmaceutical contracts. They serve compounding-pharmacy distributors like PCCA. They are not fielding orders for 500 vials from researchpeptidesusa.com. The economics don’t work at that scale: US GMP production runs hundreds to thousands of dollars per gram, and a $50 vial of 10 mg of peptide cannot have come from a US GMP facility because the math doesn’t pencil.

The Chinese supply chain that everyone depends on

China produces roughly 80% of the global generic active-pharmaceutical-ingredient supply (the exact figure varies across industry reports; 60–80% is the typical range cited). This isn’t peptide-specific — it’s the broader pharmaceutical API reality. Penicillin, statins, blood-pressure medications, antibiotics, peptide raw materials: the chemistry supply chain runs through China.

For peptides specifically: even when final synthesis happens in a US facility, the raw materials trace back to Chinese chemical supply chains. Protected amino acids, the resins SPPS attaches them to, coupling reagents, solvents — these inputs come from Chinese chemistry manufacturers. There is no US-only peptide supply chain that meaningfully exists at the input level. The CordenPharma Boulder facility uses Chinese-sourced inputs. The AmbioPharm South Carolina facility uses Chinese-sourced inputs. Even the most “US-made” pharmaceutical-grade peptide product on the market depends on the Chinese chemistry supply chain to produce its constituent building blocks.

The OEM/ODM private-label reality compounds this. Chinese manufacturers offer Original Equipment Manufacturer and Original Design Manufacturer services through platforms like Alibaba and made-in-china.com — services where a customer can buy bulk peptide and get custom branding applied to vials. Some platforms have zero-minimum-order requirements; over 190 peptides are available for private labeling. This is not a secret marketplace; it’s openly searchable on the Internet. A new “research peptide company” can be created in weeks: buy bulk product from a Chinese OEM platform, design a label, register a US LLC, set up a Shopify storefront, publish a Janoshik COA for the batch you received, and you’re a vendor.

What "Made in USA" actually means on a research-peptide label

When a US-facing research-peptide vendor claims their product is “Made in USA” or “US GMP manufactured,” that claim can mean one of four things in practice. Listed in rough order from least honest to most honest:

1. Outright misrepresentation. The vendor is sourcing Chinese product directly from an OEM platform, applying their own US-branded label, and selling it. The “Made in USA” claim is marketing fiction. Per Holyfield’s industry-insider read, “most” research-peptide companies fall in this category. That framing is more aggressive than the verifiable evidence supports — there’s a spectrum here and OHM should preserve nuance rather than collapse the whole vendor universe into “lying” — but the pattern exists.
2. US-finished, China-synthesized. A US-based vendor receives bulk shipments from China, aliquots them into vials, applies labels, and ships them out. The actual synthesis happened overseas; only the finishing and US-fulfillment steps happened on US soil. The “US-manufactured” claim is technically defensible under loose interpretations of “manufactured” — bottling and labeling are manufacturing steps — but most consumers reading “US-manufactured” would not understand this is what they’re getting.
3. Dual-facility CDMO sourcing. A vendor sources from a company like AmbioPharm with facilities in both the US and China. Production can happen at either facility based on capacity scheduling. The customer-facing vendor often doesn’t know (or doesn’t disclose) which facility produced their specific batch. The “US-made” claim is sometimes true and sometimes false depending on which batch shipped to which customer.
4. Chinese bulk, US-tested QC. A vendor receives Chinese bulk product, sends samples to a US analytical lab for third-party testing, and markets the product as “US quality control” or “US-tested.” The synthesis is Chinese; only the verification step is US-based. This is the most honest of the four interpretations but is still often presented in marketing copy that consumers read as “the molecule was made in the US.”

The uncomfortable truth: if you’re buying research peptides, you’re almost certainly using Chinese-synthesized molecules regardless of whether you paid twice as much for a “Made in USA” label. The country-of-origin marketing is not the differentiator most consumers think it is.

So what's the customer actually choosing between?

The peptide-skeptical framing of this question typically reduces to two options:

• Option 1: Go legitimate. Work with a TRT clinic or compounding pharmacy that prescribes peptides where they’re allowed (Sema/Tirz where compounding is allowed; PT-141 / Vyleesi as FDA-approved; tesamorelin for its FDA-approved indication). Pay the pharmaceutical-grade premium (often $200–1000+/month depending on compound and pharmacy). Get medical oversight and verified pharmaceutical-grade product. Accept that this is the cost of the guarantee.
• Option 2: Accept research-chemical reality. Understand these are sold “for research purposes only,” prices are low because the regulatory burden is low, find a supplier you trust based on reputation and track record, stop demanding pharmaceutical-level transparency from research-chemical vendors. Accept that the industry exists in a gray zone and that the more transparency you demand, the faster the gray zone gets enforced out of existence.

OHM’s position is that this is a false binary. There’s a third option the binary framing misses:

Option 3 — the OHM-aligned middle path:

• Buy at research-chemical prices (often 50× cheaper than US GMP pharmaceutical-grade)
• Use a verified vendor with US-based finishing, handling, customer service, and accountability (Alyve, AminoClub, BioLongevity)
• Insist on third-party Certificates of Analysis from credible labs (Janoshik, Freedom Diagnostics) — and verify the COA matches your specific batch using the techniques covered in the COA literacy article
• Accept that the molecule itself was likely synthesized in China per the global manufacturing reality above
• Accept that you’re operating in a regulatory gray zone the FDA could enforce against more aggressively at any time
• Accept that the value the verified vendor adds isn’t “US synthesis” — it’s accountability, third-party COA verification, US-based fulfillment + customer service, and reduced legal/customs/shipping risk vs direct international purchase

That’s the third option. It’s not pharmaceutical-grade; it’s not gray-market gambling. It’s the informed-adult middle path: accept the supply-chain reality you can’t change, and use the verification framework you can to close the customer-protection gap.

The "consumers demanding COAs are killing the industry" argument — engaged honestly

Some industry-insider voices (Holyfield 2026 most prominently) argue that consumer-facing COA culture is creating a regulatory paper trail that pharma companies (Eli Lilly, Novo Nordisk) will weaponize to pressure FDA enforcement, ultimately shutting down access to affordable research peptides. OHM’s editorial position is that this argument is partially true and partially overstated.

Where it’s partially true: the FDA Category 2 (“do not compound”) decision in November 2024 for ~20 peptides including BPC-157 was substantially the result of pharma + FDA convergence on enforcement against compounding lanes that compete with patented products. Eli Lilly’s Mounjaro / Zepbound revenue and Novo Nordisk’s Ozempic / Wegovy revenue are real, the patent picture is real, and pharmaceutical-industry pressure on FDA to enforce against compounding lanes that erode their revenue is a documented dynamic. The competitive dynamics around COA publishing (small mom-and-pop vendors can’t afford the testing larger vendors weaponize as differentiation) are real industry-insider observations.

Where it’s overstated: the specific mechanism — that publicly published Janoshik COAs are the FDA’s enforcement vector — does not hold up under scrutiny. FDA enforcement actions in the research-peptide space don’t trace back to COA publication. They trace back to: direct marketing claims targeting human consumption, adverse event reports, pharma-initiated complaints, customs seizures at ports, and the documented regulatory-process safety + identification + immunogenicity concerns that drove the Category 2 decision. A vendor that publishes a Janoshik COA showing 99.2% purity isn’t materially more enforceable than one that publishes no COA at all.

OHM’s editorial response in plain terms: Holyfield’s argument essentially asks the customer to choose between (a) verifying what they’re injecting and (b) preserving the research-chemical gray zone for the broader industry. OHM rejects this as a false choice. Verification protects the individual customer from the most common gray-market failure modes (mislabeled vials, contamination, fake product). It does not measurably move the regulatory-enforcement needle against the broader industry. The customer benefit of COA verification is real and concrete; the alleged regulatory cost is speculative and overstated.

That said, Holyfield IS making a real industry-insider observation about competitive dynamics. The COA-marketing-arms-race creates a barrier-to-entry that benefits the larger, better-capitalized research-peptide vendors at the expense of smaller ones. That’s a competitive-dynamics observation, not a customer-protection argument against COA literacy. Honest people can read it differently.

The takeaway

If you’re using research peptides, you’re using Chinese-synthesized molecules. Probably most of them. Possibly all of them. The “Made in USA” claim on the label most likely refers to finishing, bottling, labeling, fulfillment, customer service, accountability, US-based legal and regulatory exposure, and third-party-COA testing — not full peptide synthesis on US soil. That’s not a fraud accusation against any specific vendor; it’s the supply-chain reality of the global peptide market.

The practical OHM customer response: use a verified vendor, insist on a real third-party COA, verify the COA against your specific batch using the cap-and-seal color matching trick and 8-step verification checklist, accept the global manufacturing reality you can’t change, and don’t fall for the “US-manufactured premium” marketing if it’s not backed by the actual quality discipline. The discipline is what closes the safety gap, not the geography of synthesis.

Cross-references in the wiki

• How to read a peptide Certificate of Analysis (and spot a fake) — the verification framework that makes the OHM third option viable.
• Retatrutide — the supply-chain reality section explicitly covers the Retatrutide manufacturing-geography reality (verified Chinese synthesis predominance).
• The mainstream-medicine skeptical position — what the other side actually says — the editorial both-sides framing pattern this article extends.

---

Last updated: 2026-06-20. Created from the Holyfield “Where Peptides Actually Come From” source video with key empirical claims independently verified (Corden Pharma Boulder specifics, AmbioPharm dual-facility, CPC Scientific Hangzhou-primary status, SK Pharmteco CA timing, ~80% China API dominance, Alibaba peptide OEM/ODM reality, PCCA distributor relationships). Holyfield’s contrarian “COAs create FDA enforcement paper trail” argument engaged with serious editorial response per Doctrine #2 — neither dismissed nor uncritically adopted. The “most US-facing vendors are outright lying” framing softened to preserve nuance while still surfacing the substantive manufacturing-geography reality. All practitioner content paraphrased per Doctrine #3 — no verbatim quotes.